Predictive factors associated with weight response to exenatide in patients with type 2 diabetes mellitus
10.12092/j.issn.1009-2501.2022.03.007
- Author:
Xi SHAO
1
;
Yuhan HUANG
1
;
Xiaotong WANG
1
;
Dongmei LV
1
;
Tao WANG
1
;
Yanan YU
2
;
Hongwei LING
3
Author Information
1. Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University
2. Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University
3. Department of Endocrinology, the Affiliated Hospital of Xuzhou Medical University
- Publication Type:Journal Article
- Keywords:
Exenatide;
Predictive factor;
Type 2 diabetes;
Weight response
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(3):287-294
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To explore which variables can predict the weight response to exenatide and to individualize specific therapies for patients with type 2 diabetes mellitus (T2DM) who need treatment with exenatide. METHODS: We performed a study among T2DM patients who were treated with exenatide twice daily for at least 12 months from January 2017 to December 2020. Data of the height, weight, body mass index (BMI) calculated, and HbA1c, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting serum insulin (FINS), postprandial serum insulin (PINS), blood lipids and concurrent diabetic medications at baseline, 3 months, 6 months and 12 months after exenatide initiation were collected. Patients were categorized into two cohorts based on weight loss ≥3%: responders and non-responders. The binary logistic regression analysis was used to identify the major variables of weight response to exenatide. RESULTS: The duration of diabetes in the responder group was shorter than that in patients in the non-responder group (P<0.05). For patients in the responder and non-responder groups, there was a significant decrease in weight, BMI, HbA1c, FPG, PPG, homeostasis model assessment of insulin resistance (HOMA-IR) and increase in homeostasis model assessment for beta cell function (HOMA-B) compared with the prarameters before treatment with exenatide (P<0.001). The baseline weight and baseline HbA1c were associated with weight loss after 6 months of treatment with exenatide (P<0.05). CONCLUSION: Baseline weight and HbA1c improvement were positively correlated with weight loss after 6 months of treatment with exenatide and the major predictors of weight response to exenatide.
